stockrow
Friday 6 November 2026
Export EWTX’s income statement to Excel — free account
Edgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
- EPS
- +2,846.5%
- Free cash flow
- −30.2%
Quarter to September 2026, against a year earlier
44.89
6.02
+15.49%
Follow EWTX
Alert me
Edgewise Therapeutics, Inc. (EWTX) Net income
Edgewise Therapeutics, Inc.'s net income for fiscal 2025 was −$167.8M, compared with −$133.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.0B. Over the past ten years it has ranged from −$167.8M (fiscal 2025) to $0.00 (fiscal 2017) — the current reading is the lowest in ten years. Net income has fallen for 6 consecutive fiscal years. Edgewise Therapeutics, Inc. ranks 517th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$167.8M | — |
| FY2024 | −$133.8M | — |
| FY2023 | −$100.2M | — |
| FY2022 | −$67.6M | — |
| FY2021 | −$42.8M | — |
| FY2020 | −$17.1M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $1.2B | — |
| Jun 2026 | −$57.3M | — |
| Mar 2026 | −$49.0M | — |
| Dec 2025 | −$50.2M | — |
| 23 more quarters | Free account |
Against its own ten years
Low −$167.8M
High $0.00
Ten-year median
−$67.6M
Current reading's percentile
14
Net income against peers
| Company | Net income |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. compare | $29.9M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$56.2M |
| TNGX Tango Therapeutics, Inc. compare | −$123.7M |
| ABCL AbCellera Biologics Inc. compare | −$164.7M |
| EWTX Edgewise Therapeutics, Inc. | −$197.2M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$220.5M |
| RLAY Relay Therapeutics, Inc. compare | −$286.0M |
| DFTX Definium Therapeutics, Inc. compare | −$353.8M |
| XENE Xenon Pharmaceuticals Inc. compare | −$409.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item